492 related articles for article (PubMed ID: 24440056)
1. Endpoints in cancer clinical trials.
Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
[TBL] [Abstract][Full Text] [Related]
2. [Health related quality of life and endpoints in oncology].
Bonnetain F
Cancer Radiother; 2010 Oct; 14(6-7):515-8. PubMed ID: 20674446
[TBL] [Abstract][Full Text] [Related]
3. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
Bellera CA; Pulido M; Gourgou S; Collette L; Doussau A; Kramar A; Dabakuyo TS; Ouali M; Auperin A; Filleron T; Fortpied C; Le Tourneau C; Paoletti X; Mauer M; Mathoulin-Pélissier S; Bonnetain F
Eur J Cancer; 2013 Mar; 49(4):769-81. PubMed ID: 23122780
[TBL] [Abstract][Full Text] [Related]
4. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
McNaughton-Collins M; Walker-Corkery E; Barry MJ
J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921
[TBL] [Abstract][Full Text] [Related]
6. Endpoints for clinical trials and revised assessment in neuro-oncology.
Butowski N; Chang SM
Curr Opin Neurol; 2012 Dec; 25(6):780-5. PubMed ID: 23007010
[TBL] [Abstract][Full Text] [Related]
7. Outcomes and endpoints in trials of cancer treatment: the past, present, and future.
Wilson MK; Karakasis K; Oza AM
Lancet Oncol; 2015 Jan; 16(1):e32-42. PubMed ID: 25638553
[TBL] [Abstract][Full Text] [Related]
8. Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.
Tate Thigpen J
Gynecol Oncol; 2015 Jan; 136(1):121-9. PubMed ID: 25455732
[TBL] [Abstract][Full Text] [Related]
9. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
10. [Health-related quality of life in phase III cancer clinical trials: from questionnaire administration to statistical analysis].
Fiteni F; Anota A; Westeel V; Bonnetain F
Bull Cancer; 2015 Apr; 102(4):360-6. PubMed ID: 25799875
[TBL] [Abstract][Full Text] [Related]
11. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
12. "Just Another Statistic".
Machtay M; Glatstein E
Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology.
Fiteni F; Pam A; Anota A; Vernerey D; Paget-Bailly S; Westeel V; Bonnetain F
Expert Rev Anticancer Ther; 2015; 15(8):885-91. PubMed ID: 26027598
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in randomized trials of cytotoxic or hormonal treatment of advanced breast cancer. Is there added value?
Fossati R; Confalonieri C; Mosconi P; Pistotti V; Apolone G
Breast Cancer Res Treat; 2004 Oct; 87(3):233-43. PubMed ID: 15528966
[TBL] [Abstract][Full Text] [Related]
15. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
[TBL] [Abstract][Full Text] [Related]
16. Interpreting clinical trials in lung cancer: impact of methodology and endpoints.
Gralla RJ; Griesinger F
J Thorac Oncol; 2007 Jun; 2 Suppl 2():S51-8. PubMed ID: 17589300
[TBL] [Abstract][Full Text] [Related]
17. The current role and limitations of surrogate endpoints in advanced prostate cancer.
Gomella LG; Oliver Sartor A
Urol Oncol; 2014 Jan; 32(1):28.e1-9. PubMed ID: 23433893
[TBL] [Abstract][Full Text] [Related]
18. [Surrogate and true endpoints in cancer clinical trials].
Nakajima T; Ohta K; Ohyama S; Yamaguchi T
Gan To Kagaku Ryoho; 2000 May; 27(5):671-5. PubMed ID: 10832433
[TBL] [Abstract][Full Text] [Related]
19. Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials.
Matulonis UA; Oza AM; Ho TW; Ledermann JA
Cancer; 2015 Jun; 121(11):1737-46. PubMed ID: 25336142
[TBL] [Abstract][Full Text] [Related]
20. Surrogate endpoints for overall survival in lung cancer trials: a review.
Fiteni F; Westeel V; Bonnetain F
Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
